Daptomycin
Also known as: Cubicin, Cubicin RF, LY146032, cyclic lipopeptide antibiotic, daptomycin for injection
Cyclic lipopeptide antibiotic — calcium-dependent antimicrobial peptide; Gram-positive-specific bactericidal agent
What it is
Daptomycin (Cubicin) is an intravenous antibiotic used in hospitals to treat serious, life-threatening infections caused by resistant bacteria — especially MRSA and drug-resistant enterococci — when standard antibiotics have failed or are not tolerated. It is a last-resort treatment option used exclusively in clinical settings under physician supervision.
The scientific side
daptomycin is a cyclic lipopeptide antibiotic isolated from Streptomyces roseosporus that exerts bactericidal activity against Gram-positive bacteria through a calcium-dependent, membrane-disruption mechanism distinct from all other approved antibiotic classes. The mechanism proceeds in two sequential stages: a rapid, reversible initial binding of daptomycin to the bacterial phospholipid membrane occurring within milliseconds, followed by a slower, irreversible insertion into the membrane that occurs over minutes and critically requires the bacteria-specific anionic phospholipid phosphatidylglycerol (PG). Daptomycin simultaneously binds two molecules of PG in a 1:2 drug-to-PG ratio to reach a saturating membrane insertion point. Calcium ions are essential cofactors: they facilitate daptomycin oligomerization and anchor the lipid tail of the molecule into the bacterial membrane, causing disruption of membrane potential, pore formation, and rapid bacterial cell death without lysis. The cholesterol content of the target membrane modulates this interaction — human cell membranes, which are cholesterol-rich and PG-poor, are therefore spared. Daptomycin also sequesters lipid II, a key precursor in bacterial cell wall synthesis, contributing to disruption of peptidoglycan biosynthesis alongside primary membrane damage, which overproduces reactive oxygen species resulting in cell death. Daptomycin's activity is concentration-dependent, and a strong inoculum effect has been described — MIC values rise markedly at high bacterial cell counts, a phenomenon relevant to high-burden infections such as biofilm-associated device infections and infective endocarditis. Resistance to daptomycin in Staphylococcus aureus is primarily mediated by mutations in MprF, which increases production of cationic lysyl-phosphatidylglycerol on the outer membrane leaflet, raising the positive surface charge and repelling daptomycin binding. In Enterococcus, resistance mechanisms include alterations in cell membrane phospholipid composition and LiaFSR two-component system mutations. Crucially, daptomycin is inactivated by pulmonary surfactant in the alveolar space through competitive interaction with phosphatidylglycerol, rendering it ineffective against pneumonia — a key clinical limitation.
Class: Cyclic lipopeptide antibiotic — calcium-dependent antimicrobial peptide; Gram-positive-specific bactericidal agent
Administration & storage
- Administration
- IV infusion over 30 minutes following dilution in 50 mL 0.9% NaCl (standard Cubicin administration)IV bolus injection over 2 minutes using Cubicin RF reconstituted formulation (FDA-approved alternative for bacteremia/endocarditis dosing)Subcutaneous injection at 10 mg/kg investigated in Phase I trial (PMID: 39271104) — not FDA-approved; investigational for OPAT settings with difficult venous access
- Storage
- Unopened vials: store in refrigerator at 2–8°C (36–46°F). Do not freeze. Protect from light. Reconstituted solution (50 mg/mL in vial): stable for 12 hours at room temperature or 48 hours refrigerated. Diluted solution in 50 mL 0.9% NaCl: stable for 12 hours at room temperature or 48 hours refrigerated. Total storage time (reconstituted + diluted) should not exceed 12 hours at room temperature or 48 hours refrigerated.
- Cautions
- Myopathy and rhabdomyolysis: Daptomycin can cause skeletal muscle toxicity manifesting as myalgia, muscle weakness, and CPK elevation. Rhabdomyolysis is a known, potentially fatal adverse effect. Baseline CPK measurement required before initiation; CPK monitoring weekly during therapy (every 48–72 hours for high-dose use). Discontinue if CPK rises >1,000 U/L (>5x ULN) with symptoms, or >2,000 U/L without symptoms. Statin co-administration significantly increases risk — statins should be temporarily suspended during daptomycin therapy where possible (PMIDs: 34902879, 29668884).,Daptomycin-associated eosinophilic pneumonia (DAEP): A serious, idiosyncratic pulmonary toxicity that can be fatal if unrecognized. Presents with new or worsening respiratory symptoms, fever, new pulmonary infiltrates, and peripheral eosinophilia, typically after 2–4 weeks of therapy. Requires immediate discontinuation of daptomycin and corticosteroid therapy. Distinct from daptomycin's known inactivation by lung surfactant (which is a pharmacological effect, not a toxicity).,Drug inactivation by pulmonary surfactant — NOT for pneumonia: Daptomycin binds to pulmonary surfactant phospholipids (especially phosphatidylglycerol) and is rendered inactive in the lung parenchyma. Daptomycin must never be used for pneumonia, including lung infections caused by otherwise susceptible Gram-positive organisms. This is an FDA black-box class warning.,Peripheral neuropathy: Sensory and motor peripheral neuropathy has been reported, particularly with prolonged courses. Neurological monitoring is recommended for extended therapy. Mechanism is unclear but may be related to membrane disruption in peripheral nerve sheaths.,QTc interval monitoring: Although QT prolongation is less commonly associated with daptomycin than with other antibiotics, clinical vigilance is warranted in patients with pre-existing cardiac conditions or on QT-prolonging co-medications.,Statin drug interaction — myopathy risk amplification: A systematic review and meta-analysis found that concomitant statin use significantly increases the incidence of CPK elevation (defined as ≥5x ULN) during daptomycin therapy. A matched case-control study confirmed statin co-administration as a risk factor for daptomycin-associated myopathy. Temporary statin discontinuation during daptomycin courses is strongly recommended.,Resistance emergence during therapy: Daptomycin non-susceptibility can develop during treatment of VRE and MRSA infections, particularly in patients receiving subtherapeutic doses or with high bacterial inocula. Therapeutic drug monitoring (TDM) and dose optimization are recommended for severe infections.
Legal & regulatory status
FDA-approved (NDA 021572) as Cubicin (daptomycin for injection) for the treatment of complicated skin and skin structure infections (cSSSI) caused by susceptible Gram-positive organisms (approved September 2003), and…
Daptomycin is not listed on the WADA Prohibited List. It is a therapeutic antibiotic without performance-enhancing properties and has no relevance to competitive sport doping regulations. No WADA classification applies.…
Approved in Canada as Cubicin (daptomycin for injection) for the treatment of complicated skin and skin structure infections caused by susceptible Gram-positive bacteria and for Staphylococcus aureus bloodstream…
What it's studied for
- Complicated skin and skin structure infections (cSSSI) — FDA-approved indication Phase III RCT
- Staphylococcus aureus bacteremia and right-sided infective endocarditis — FDA-approved indication Phase III RCT
- Vancomycin-resistant Enterococcus (VRE) bloodstream infections — off-label but guideline-supported Human observational
- MRSA bacteremia combination therapy — daptomycin plus beta-lactam synergy Phase III RCT
- Pediatric infections — off-label use in children with resistant Gram-positive infections Human observational
- High-dose daptomycin (8–12 mg/kg) for severe/refractory MRSA and VRE infections — off-label Human observational
- Bone, joint, and prosthesis-related infections — off-label Mixed
Safety signals
- Skeletal muscle toxicity — myopathy and rhabdomyolysis (including CPK elevation)
- Daptomycin-associated eosinophilic pneumonia (DAEP)
- Drug inactivation in the lung — pharmacological failure if used for pneumonia
- Daptomycin resistance emergence during treatment (VRE and MRSA)
- Peripheral neuropathy
- Statin drug interaction amplifying myopathy risk
- Inoculum effect — reduced bactericidal activity at high bacterial cell counts
All studies (12)
Frequently asked
Why can't daptomycin be used to treat pneumonia?
Daptomycin is inactivated by pulmonary surfactant, the lipid layer coating the alveoli (air sacs) in the lungs. Surfactant contains large amounts of phosphatidylglycerol — the same lipid that daptomycin must bind to exert its antibiotic effect on bacteria. When daptomycin reaches the lung, surfactant competes for and sequesters the drug before it can reach bacteria, rendering it inactive. This is a well-characterized pharmacological limitation, not a side effect, and is the reason daptomycin is contraindicated for pneumonia even when caused by bacteria that appear susceptible in lab testing.
What muscle side effects should I watch for during daptomycin treatment?
Daptomycin can cause muscle toxicity (myopathy) in some patients. Warning signs include muscle pain, tenderness, weakness, or cramps — particularly in the limbs or back. If you notice these symptoms, contact your medical team immediately. Your care team should be monitoring your creatine phosphokinase (CPK or CK) blood levels before starting treatment and at least weekly during therapy. If you are also taking a statin (cholesterol-lowering medication), your physician may temporarily pause the statin during daptomycin treatment, as statins substantially increase the risk of muscle problems when combined with daptomycin (PMIDs: 34902879, 29668884).
Is daptomycin the same as vancomycin?
No — daptomycin and vancomycin are different antibiotics that target the same type of bacteria (Gram-positive organisms including MRSA) but through completely different mechanisms and with different clinical profiles. Vancomycin is a glycopeptide that inhibits cell wall synthesis from outside the membrane. Daptomycin is a cyclic lipopeptide that disrupts the bacterial cell membrane directly in a calcium-dependent manner. Key differences: daptomycin is bactericidal (kills bacteria directly); it cannot be used for lung infections (unlike vancomycin); it requires muscle enzyme monitoring (CPK); and it is inactivated by pulmonary surfactant. Vancomycin requires monitoring for kidney toxicity and blood level (trough/AUC) monitoring.
Can daptomycin be given as a subcutaneous injection instead of IV?
Standard daptomycin (Cubicin) is approved only for intravenous administration. However, a Phase I randomized crossover trial evaluated subcutaneous daptomycin at 10 mg/kg in healthy volunteers with no medical history and found that subcutaneous bioavailability was comparable to IV in terms of total drug exposure (AUC), though peak concentration (Cmax) was lower. This approach is not currently FDA-approved and remains investigational. It may be considered in specialized outpatient settings by physicians for patients with difficult venous access, but only under careful medical supervision.
What is daptomycin used for in hospitals?
Daptomycin (Cubicin) is a hospital-use intravenous antibiotic prescribed for serious infections caused by resistant Gram-positive bacteria. Its two FDA-approved uses are: (1) complicated skin and skin structure infections (including those caused by MRSA), at 4 mg/kg once daily; and (2) Staphylococcus aureus bloodstream infections (bacteremia) and right-sided infective endocarditis, at 6 mg/kg once daily. Off-label, it is widely used for vancomycin-resistant enterococcal (VRE) infections and for bone/joint/prosthetic device infections caused by MRSA or resistant enterococci. It is reserved for cases where standard antibiotics have failed or cannot be used safely.